期刊文献+

哌拉西林与加替沙星联用对铜绿假单胞菌的联合药敏研究 被引量:6

The Study on the Antibacterial Activity of Piperacillin Combine with Gatifloxacin Against Pseudomonas Aeruginosa
在线阅读 下载PDF
导出
摘要 目的 评价哌拉西林与加替沙星联合用药,对30株临床分离的铜绿假单胞菌的体外抗菌效应。方法 采用棋盘法设计,微量肉汤稀释法测定。测定不同浓度组合的抗菌药物对30株临床分离的铜绿假单胞菌的最低抑菌浓度,并计算FIC指数判定联合效应。FIC≤0 .5为协同作用,0 .5 <FIC≤1为相加作用,1<FIC≤2为无关作用,FIC >2为拮抗作用。结果 哌拉西林与加替沙星联用后,其MIC50 显著降低。FIC指数分布:FIC≤0 .5占4 0 % ;0 .5 <FIC≤1占5 0 % ;1<FIC≤2占10 % ;FIC >2为0。结论 结果表明两药联用,对铜绿假单胞菌表现为协同作用和相加作用,并以协同作用为主,无关作用较少,更无拮抗作用。 Aim To evaluate the antibiotic effects of piperacill in combined with gatifloxacin against 30 strains of Pseudomonas aeruginosa. Methods The protocol was designed by checkerboard method and the MICs of piperacillin or/and combined with other 6 antibiotics against the 30 strains of Pseudomonas aeruginosa were determined by broth dilution method,the FIC index was calculated according to MIC results.Results The perc entage of the FIC indexes less than 0.5,from 0.5 to 1,from 1 to 2,more than 2 we re 40%,50%,10%,0% respectively.Conclusion The results suggested t hat synergism and additivity of piperacillin combined with gatifloxacin respecti vely against 30 strains of Pseudomonas aeruginosa were main action,there wer e little autonomy and no antagonism.
出处 《解放军药学学报》 CAS 2005年第2期121-123,共3页 Pharmaceutical Journal of Chinese People's Liberation Army
  • 相关文献

参考文献8

  • 1王辉,陈民钧,中国医院内病原菌耐药监测网.1994~2001年中国重症监护病房非发酵糖细菌的耐药变迁[J].中华医学杂志,2003,83(5):385-390. 被引量:422
  • 2陈民钧,王辉,中国医院内病原菌耐药监测网.中国重症监护病房革兰阴性菌耐药性连续7年监测研究[J].中华医学杂志,2003,83(5):375-381. 被引量:504
  • 3Sahm DF,Washington II JA.Antibacterial susceptibility tests :dilution methods[J].Manual of clinical microbiology,1995,6:1117.
  • 4George M,Eliopoulos,Robert C.Moellering,JR.Antimicrobial Combinations[J].Antibootics in Laboratory Medicine,1996,4:330.
  • 5Cornaglia G,Mazzariol A,Lauretti L,et al.Hospital outbreak of carbapenem-resistant.Pseudomonas aeruginosa producing VIM-1,a novel transferable metallo-beta-lactamase[J].Clin Infect Dis,2000,31:1119.
  • 6Appelbaum PC.Quinolone activity against anaerobes[J].Drugs,1999,58(Suppl 2):60.
  • 7Takei M,Fukuda H,Yasue T,et al.Inhibitory activities of gatifloxacin (AM-1155),a newly developed fluoroquinolone,against bacterial and mammalian typeⅡ topoisomerase[J].Antimicro Agents Chemother,1998,42(20):2678.
  • 8Dudley M N,Blaser J,Gilber D,et al.Combination therapy with ciprofloxacin plus azlocillin against Psedomonas aeruginosa :effect of simultaneous versus staggered administration in an in vitro model of infection[J].J Infect Dis,1991,164:499.

二级参考文献18

  • 1Itokazu GS, Quinn JP, Bell-Dixon C, et al. Antimicrobial resistance rates among aerobic gram-negative bacilli recovered from patients in intensive-care units: evaluation of a national postmarketing surveillance program. Clin Infect Dis, 1996, 23: 779-784.
  • 2Jarvis WR, Martone WJ. Predominant pathogens in hospital infections. J Antimicrob Chemother, 1992, 29(suppl A): 19-24.
  • 3Hilf M, Yu VL, Sharp J, et al. Antibiotic therapy for Psedomonas aeruginosa bacteriemia: outcome correlations in a prospective study of 200 patients. Am J Med, 1989, 87:540-546.
  • 4Lanson EL. Persistent carriage of gram-negative bacteria on hands. Am J Infect Control, 1981, 9: 112-119.
  • 5Urban C, Go E, Mariano N, et al. Effect of sulbactam on infections caused by imipenem-resistant Acinetobacter calcoaceticus biotype anitratus. J Infect Dis, 1993, 167: 448-451.
  • 6Ang SW, Lee ST. Emergence of a multiple-resistant strain of Acinetobacter in a bums unit. Ann Acad Med Singapore, 1992, 21:660-603.
  • 7Murray PR, Baron E J, Pfaller MA, et al. Manual of clinical laboratory.7th Edition. Washington DC: American Society for Microbiology, 1999,552-554.
  • 8Quinn JP. Clinical problem posed by multiresistant nonfermenting gramnegative pathogens. Clin Infect Dis, 1998, 27(Suppl 1 ): S117-124.
  • 9Bergogne-Berezin E. Guideline on antimicrobial chemotherapy for prevention and treatment of infections in the ICU. J Chemother, 2001,1: 134-149.
  • 10Goossens H. MYSTIC program: summary of European data from 1997 to 2000. Diagn Microbiol Infect Dis, 2001, 41: 183-189.

共引文献892

同被引文献45

引证文献6

二级引证文献43

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部